1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Quest PharmaTech Inc.

Quest PharmaTech Inc.

QPTFF
Quest PharmaTech Inc.US flagOther OTC
0.02
USD
- -
- -
3.38MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.02
-0.04
-0.02
-0.03
-0.03
-0.04
1.13
-0.51
-0.39
-0.02
-0.01
0.03
- -
Free Cash Flow per Basic Share
-0.02
-0.02
-0.02
-0.03
-0.05
-0.04
-0.04
-0.02
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.36
-0.31
-0.3
-0.26
-0.1
-0.12
-0.16
0.98
0.47
0.09
0.07
0.06
0.09
0.18
Tangible Book Value per Share
-0.03
-0.04
-0.02
-0.04
0.02
-0.03
-0.1
1.04
0.54
0.15
0.14
0.13
0.16
0.13
Basic Weighted Avg Shares
87
104
123
150
159
167
167
168
168
168
169
169
169
169
Sales/Revenue/Turnover
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-8.54
- -
- -
-168,036.55
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-5
-2
-5
-4
-6
190
-85
-65
-3
-2
5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-14.12
- -
- -
-95,765.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-2
-4
-12
9
2
-6
-18
- -
- -
- -
- -
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-2
-4
-2
11
3
-4
-16
175
90
26
23
21
26
22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-1.32
- -
- -
- -
- -
-2.86
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
271.95
- -
- -
- -
- -
37.57
70.88
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
-69.75
-137.96
-22.92
-16.74
40.45
-1.18

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
169
169
169
Market Capitalization
3
3
3

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-185.92%
-22.79%
23.51%
Free Cash Flow
14.62%
15.99%
-62.74%
Net Income, GAAP
-376.84%
-136.33%
-377.52%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
-0.01
- -
- -
- -
-0.01
2026
- -
0.01
- -
- -
0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ragupathy Madiyalakan
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
8123 Roper Road NW Edmonton AB Canada T6E 6S4
IPO Date
Aug 24, 2018
Website
questpharmatech.com
Similar Companies
Rebus Holdings, Inc. (RBSH)
Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
Photocure ASA (PHCUF)
Navidea Biopharmaceuticals, Inc. (NAVBQ)
ERYTECH Pharma S.A. (ERYP.PA)
Kintara Therapeutics, Inc. (KTRA)
Business
Quest PharmaTech Inc. (TSX-V: QPT; OTC: QPTFF) is a Canada-based biopharmaceutical company that develops products to improve quality of life through proprietary technologies and equity investments in immunotherapy ventures; it focuses on antibody-based immunotherapeutic products and theranostic agents for cancer treatment, including its lead proprietary monoclonal antibody Mab AR 9.6, licensed from the University of Nebraska Medical Center, which targets truncated O-glycan on MUC16 for potential applications in pancreatic, colon, leukemia, ovarian, and breast cancers and remains in late preclinical development. The company holds a 42.5% ownership interest in OncoQuest Inc., which previously developed and sold immunotherapy assets including oregovomab; a 23% stake in OncoVent, a Chinese joint venture advancing antibody-based cancer immunotherapeutics for the Greater China market; and, following the conversion of its OQP Bio bonds in February 2025, a 26.25% equity position as the largest shareholder in OQPBIOM Inc., a private South Korean firm developing former OncoQuest immunotherapy assets and other cancer treatments stemming from the original 2020 asset sale to Dual Industrial Co. Ltd. Founded in 1996 and headquartered at 4342 97 Street NW, Edmonton, Alberta, T6E 5R9, Canada, Quest operates primarily in the biotechnology sector with global investee exposure across North America, China, and South Korea. In June 2025, Quest publicly opposed and refused support for OQPBIOM's unconsulted acquisition of a controlling interest in South Korea's KOSDAQ-listed AdBioTech Co. Ltd., citing risks to stable funding for oregovomab's Phase 3 clinical trials in ovarian cancer and incompatibility with shareholder interests, while evaluating legal options; the company also filed its fiscal year-end January 31, 2025 financials in June 2025, reporting total assets of $22.6 million including the pre-conversion bonds valued at $17 million.

Company News

APIChatGPT

  • globenewswire.com

    Quest PharmaTech Announces Results from AGM

  • globenewswire.com

    Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech